Details for Patent: 8,314,097

Which drugs does patent 8,314,097 protect, and when does it expire?

Patent 8,314,097 protects ISTURISA and is included in one NDA.

This patent has fifty-three patent family members in thirty-four countries.

Summary for Patent: 8,314,097

Title:	Organic compounds
Abstract:	The present invention provides a compound of formula I: ##STR00001## Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy. Finally, the present invention also provides a pharmaceutical composition.
Inventor(s):	Ksander; Gary Michael (Amherst, NH), Meredith; Erik (Hudson, MA), Monovich; Lauren G. (Belmont, MA), Papillon; Julien (Somerville, MA), Firooznia; Fariborz (Florham Park, NJ), Hu; Qi-Ying (Needham, MA)
Assignee:	Novartis AG (Basel, CH)
Application Number:	11/508,445
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 8,314,097

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Recordati Rare	ISTURISA	osilodrostat phosphate	TABLET;ORAL	212801-001	Mar 6, 2020		RX	Yes	No			Y	Y
Recordati Rare	ISTURISA	osilodrostat phosphate	TABLET;ORAL	212801-002	Mar 6, 2020		RX	Yes	No			Y	Y
Recordati Rare	ISTURISA	osilodrostat phosphate	TABLET;ORAL	212801-003	Mar 6, 2020		DISCN	Yes	No			Y	Y

International Family Members for US Patent 8,314,097

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	057772
Australia	2006283105
Brazil	PI0615095
Canada	2619660
China	101248078
China	102408429
Cyprus	1114349